Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/11739
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBrisson, Gisele Dallapicola-
dc.contributor.authorLopes, Bruno de Almeida-
dc.contributor.authorAndrade, Francianne Gomes-
dc.contributor.authorBueno, Filipe Vicente dos Santos-
dc.contributor.authorCezar, Ingrid Sardou-
dc.contributor.authorGonçalves, Bruno Alves de Aguiar-
dc.contributor.authorPina, Eugênia Terra Granado-
dc.date.accessioned2022-12-16T14:13:09Z-
dc.date.available2022-12-16T14:13:09Z-
dc.date.issued2018-
dc.identifier.citationBRISSON, Gisele Dallapicola et al. EPHX1 rs1051740 T>C (Tyr113His) is strongly associated with acute myeloid leukemia and KMT2A rearrangements in early age. Archives of Toxicology, v. 92, p. 2001–2012, 2018.-
dc.identifier.issn1432-0738-
dc.identifier.urihttps://ninho.inca.gov.br/jspui/handle/123456789/11739-
dc.descriptionp. 2001–2012.: tab. p&b.-
dc.description.abstractExperimental and epidemiological data have shown that acute myeloid leukemia in early-age (i-AML) originates prenatally. The risk association between transplacental exposure to benzene metabolites and i-AML might be influenced by genetic susceptibility. In this study, we investigated the relationship between genetic polymorphisms in CYP2E1, EPHX1, MPO, NQO1, GSTM1 and GSTT1 genes, and i-AML risk. The study included 101 i-AMLs and 416 healthy controls. Genomic DNA from study subjects was purified from bone marrow or peripheral blood aspirates and genotyped for genetic polymorphisms by real-time PCR allelic discrimination, Sanger sequencing and multiplex PCR. Crude and adjusted odds ratios (OR, adjOR, respectively) with 95% confidence intervals (95% CI) were assessed using unconditional logistic regression to estimate the magnitude of risk associations. EPHX1 rs1051740 T>C was associated with i-AML risk under the co-dominant (adjOR 3.04, P=0.003) and recessive (adjOR 2.99, P=0.002) models. In stratified analysis, EPHX1 rs1051740 was associated with increased risk for i-AML with KMT2A rearrangement (adjOR 3.06, P=0.045), i-AML with megakaryocytic differentia tion (adjOR 5.10, P=0.008), and i-AML with type I mutation (adjOR 2.02, P=0.037). EPHX1 rs1051740-rs2234922 C-G haplotype was also associated with increased risk for i-AML (adjOR 2.55, P=0.043), and for i-AML with KMT2A rear rangement (adjOR 3.23, P=0.034). Since EPHX1 enzyme is essential in cellular defense against epoxides, the diminished enzymatic activity conferred by the variant allele C could explain the risk associations found for i-AML. In conclusion, EPHX1 rs1051740 plays an important role in i-AML’s genetic susceptibility by modulating the carcinogenic effects of epoxide exposures in the bone marrow.pt_BR
dc.publisherArchives of Toxicology-
dc.subjectEpóxido Hidrolasespt_BR
dc.subjectEpoxide Hydrolasespt_BR
dc.subjectEPHX1pt_BR
dc.subjectKMT2A/MLL-rpt_BR
dc.subjectLactentept_BR
dc.subjectInfantpt_BR
dc.subjectPolimorfismo Genéticopt_BR
dc.subjectPolymorphism Geneticpt_BR
dc.titleEPHX1 rs1051740 T>C (Tyr113His) is strongly associated with acute myeloid leukemia and KMT2A rearrangements in early agept_BR
dc.TypeArticlept_BR
Appears in Collections:Artigos de Periódicos da área de Pediatria



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.